Abstract:Abstract While a number of low-frequency genetic variants of large effect size have been shown to underlie both cardiovascular disease and dementia, recent studies have highlighted the importance of common genetic variants of small effect size, which, in aggregate, are embodied by a polygenic risk score. We investigate the effect of polygenic risk for coronary artery disease on brain atrophy in Alzheimer’s disease using whole-brain volume and put our findings in context with the polygenic risk for Alzheimer’s disease and presumed small vessel disease as quantified by white-matter hyperintensities. We use 730 subjects from the Alzheimer’s disease neuroimaging initiative database to investigate polygenic risk score effects (beyond APOE) on whole-brain volumes, total and regional white-matter hyperintensities and amyloid beta across diagnostic groups. In a subset of these subjects (N = 602), we utilized longitudinal changes in whole-brain volume over 24 months using the boundary shift integral approach. Linear regression and linear mixed-effects models were used to investigate the effect of white-matter hyperintensities at baseline as well as Alzheimer’s disease-polygenic risk score and coronary artery disease-polygenic risk score on whole-brain atrophy and whole-brain atrophy acceleration, respectively. All genetic associations were examined under the oligogenic (P = 1e-5) and the more variant-inclusive polygenic (P = 0.5) scenarios. Results suggest no evidence for a link between the polygenic risk score and markers of Alzheimer’s disease pathology at baseline (when stratified by diagnostic group). However, both Alzheimer’s disease-polygenic risk score and coronary artery disease-polygenic risk score were associated with longitudinal decline in whole-brain volume (Alzheimer’s disease-polygenic risk score t = 3.3, PFDR = 0.007 over 24 months in healthy controls) and surprisingly, under certain conditions, whole-brain volume atrophy is statistically more correlated with cardiac polygenic risk score than Alzheimer’s disease-polygenic risk score (coronary artery disease-polygenic risk score t = 2.1, PFDR = 0.04 over 24 months in the mild cognitive impairment group). Further, in our regional analysis of white-matter hyperintensities, Alzheimer’s disease-polygenic risk score beyond APOE is predictive of white-matter volume in the occipital lobe in Alzheimer’s disease subjects in the polygenic regime. Finally, the rate of change of brain volume (or atrophy acceleration) may be sensitive to Alzheimer’s disease-polygenic risk beyond APOE in healthy individuals (t = 2, P = 0.04). For subjects with mild cognitive impairment, beyond APOE, a more inclusive polygenic risk score including more variants, shows coronary artery disease-polygenic risk score to be more predictive of whole-brain volume atrophy, than an oligogenic approach including fewer larger effect size variants.

Endocytosis-pathway polygenic scores affects the hippocampal network connectivity and individualized identification across the high-risk of Alzheimer’s disease

ENDOCYTOSIS MULTILOCUS GENETIC PROFILE AFFECTS HIPPOCAMPAL NETWORK CONNECTIVITY AND INDIVIDUALIZES IDENTIFICATION ACROSS THE PRODROMAL STAGES OF ALZHEIMER’S DISEASE

Polygenic Hazard Score Associated Multimodal Brain Networks along the Alzheimer's Disease Continuum.

Polygenic hazard score modified the relationship between hippocampal subfield atrophy and episodic memory in older adults

Polygenic Effects of the Lipid Metabolic Pathway Accelerated Pathological Changes and Disrupted Default Mode Network Trajectory Across the Alzheimer’s Disease Spectrum

Polygenic effect of cholesterol metabolism pathway‐accelerated pathological changes and disrupted default mode network trajectory across the Alzheimer’s disease spectrum

Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals

Structural Covariance Network as an Endophenotype in Alzheimer’s Disease-Susceptible Single-Nucleotide Polymorphisms and the Correlations With Cognitive Outcomes

Polygenic Risk for Alzheimer's Disease Influences Precuneal Volume in Two Independent General Populations

Genome-Wide Association Analysis across Endophenotypes in Alzheimer's Disease: Main Effects and Disease Stage-Specific Interactions

Integrating amyloid imaging and genetics for early risk stratification of Alzheimer's disease

Integration of Multilocus Genetic Risk into the Default Mode Network Longitudinal Trajectory During the Alzheimer'S Disease Process

Integrated Identification of Key Genes and Pathways in Alzheimer’s Disease Via Comprehensive Bioinformatical Analyses

Polygenic coronary artery disease association with brain atrophy in the cognitively impaired

Multiple Genetic Imaging Study of the Association Between Cholesterol Metabolism and Brain Functional Alterations in Individuals with Risk Factors for Alzheimer's Disease

Mapping the Genetic-Imaging-Clinical Pathway with Applications to Alzheimer's Disease

Genetics Pathway-Based Imaging Approaches in Chinese Han Population with Alzheimer’s Disease Risk

Brain network fingerprints of Alzheimer's disease risk factors in mouse models with humanized APOE alleles

Synergistic Effects of <i>APOE</i> and <i>CLU</i> May Increase the Risk of Alzheimer's Disease: Acceleration of Atrophy in the Volumes and Shapes of the Hippocampus and Amygdala

Multivariate genome wide association and network analysis of subcortical imaging phenotypes in Alzheimer's disease

Polygenic Effects of Schizophrenia on Hippocampal Grey Matter Volume and Hippocampus–medial Prefrontal Cortex Functional Connectivity